clinical oncology Articles
-
Scripps MD Anderson Cancer Center: SCC of Right Index Fingernail - Case Study
The following patient case demonstrates the application of Adaptiiv’s technology used in clinical radiation oncology through the design and fabrication of customized bolus to improve the efficacy of treating complex target volumes with electron beams. This case is a great example of how a custom modulated electron bolus (MEB) allowed for a uniform dose distribution of a complex treatment ...
-
Navigating Cancer’s, Dr. Amila Patel, Provides Insight on Racial Disparities in Recent Cancer Treatment Study
Navigating Cancer, Chief Clinical & Strategy Officer, Dr. Amila Patel, PharmD, BCOP, recently presented data on key findings from a recent abstract with Duke Health revealing racial disparities among head and neck cancer populations at the 2022 American Society of Clinical Oncology conference. Our research, along with our partners at Duke Health, found there were significant health care ...
-
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study (American Society of Clinical Oncology)
Worldwide, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths in women, with over 650,000 deaths in 2020.1,2 Human epidermal growth factor receptor 2 (HER2)-targeted agents have improved outcomes in HER2-positive breast cancer, but most patients in first-line therapy do not respond to current therapies, eventually relapse or develop ...
-
A Combination of Ramucirumab Plus Pembrolizumab Lengthened Survival For Some Lung Cancer Patients
A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that when treated with a combination of ramuzumab (Cyramza) and Keytruda, Patients with advanced NSCLC whose cancer progressed during prior immunotherapy lived significantly longer than when treated with one of the current standard therapies for this cancer. The hazard ratio (80% confidence interval) for overall survival ...
-
Navigating Cancer in Collaboration with Experts in Oncology Present Key Research at 2022 ASCO Annual Meeting on Using Digital Health Solutions to Bridge the Health Equity Gap
Navigating Cancer in collaboration with Texas Oncology executes large-scale patient engagement study revealing high digital health solution engagement while demonstrating the opportunity to increase support for diverse patient populations. Scientific and technological advancements have helped enhance cancer care and access to care. Indeed, an important silver lining in the pandemic has been the ...
-
Key Takeaways from BIO 2022 for AI-enabled Drug Discovery
It was great to be back in person at the 2022 BIO International Convention this year. It came as no surprise to us at Recursion that artificial intelligence (AI) and machine learning (ML) were hot topics at the conference, with more than half a dozen sessions exploring how these technologies are driving digital transformation in biopharma. We heard from leaders who are applying AI at ...
By Recursion
-
Introducing Navigating Cancer’s Medical Advisory Board Ahead of ASCO Presentations Illustrating Equitable Cancer Care Innovation
Navigating Cancer is filling an important role in the healthcare community during a time that has placed tremendous pressure on healthcare providers to better support a growing and diverse patient population, outside-of-the-clinic. Digital health tools and remote symptom monitoring enable more efficient care delivery and improve patient outcomes – while providing actionable insights based ...
-
Enhancing Oncology Model: New CMS value-based payment model aims to improve health equity and patient-centered care
Just days before the sunset of the CMS Oncology Care Model, CMS announced its new Enhancing Oncology Model (EOM), the new value-based care oncology payment model. Rolled out as part of the Biden-Harris Administration’s Cancer Moonshot, the goal of EOM is to improve the experience of cancer patients, while advancing health equity and increasing access to care, as well as reducing Medicare ...
-
5 year trial involving ovarian cancer patients has found “overall survival benefits” when undergoing surgery using PlasmaJet
A trial involving ovarian cancer patients at Guildford’s Royal Surrey Hospital (UK) has found they have a higher chance of having all the tumour removed when undergoing surgery using argon plasma. Patients who participated in the ‘PlasmaJet® in Ovarian Cancer Surgery’ feasibility study were given a preview of the results as part of Ovarian Cancer Awareness Month recently. ...
-
Oncology - Complex Clinical Trials in The Fastest Growing Therapeutic Area
In the developed world, 1 in 4 people die from cancer or cancer-related disease, and cancer accounts for 13% of deaths globally. Oncology is the fastest growing therapeutic area by revenue and number of clinical trials. There’s been a huge emphasis on developing new treatments to improve survival in patients with cancer, but these trials have become a costly undertaking for sponsor ...
-
Why You Should Ask Your Doctor About Principal Care Management
A cancer diagnosis is a life-changing event. The diagnosis alone is daunting and then suddenly you are faced with difficult decisions – decisions that may affect your care and quality of life. Cancer is a 24/7 diagnosis, it affects daily life and routines. Symptoms and side effects present themselves on their own schedule, not necessarily when it is convenient for you. Recognizing the ...
-
Researchers highlight the impact of COVID 19 pandemic on patients with cancer
New collaborative research from Queen’s University Belfast, the University of Split, Croatia and King’s College London has shown that the response to the outbreak of the coronavirus disease 2019 (COVID-19) is significantly affecting the treatment and care of patients with cancer. The research, recently published in the European Journal of Cancer, highlights how the repurposing of ...
-
Case Studies Utilizing KUBTEC Mozart 3D Tomosynthesis for Margin Management during Partial Mastectomy by Kandace P. McGuire, MD - Case Study
Dr. Kandace P. McGuire shares how 3D tomosynthesis assisted her during two cases (The Case of the Missing Magseed & Imaging a Bracketed Lesion). In addition, Dr. McGuire discusses how she evaluated the specimens in multiple ways using KUBTEC’s MOZART ...
-
How 4D Path and PathPresenter aim to further AI-enabled digital pathology for breast tumor profiling
The digital pathology software company PathPresenter (Montville, New Jersey) and the precision oncology platform firm 4D Path have entered into a partnership that could improve the diagnostic accuracy of breast tumor profiling. PathPresenter has developed a digital workflow tool for clinicians, pathologists and pharma companies to aggregate medical data. ...
By 4D Path Inc.
-
Spatial profiling of chromatin accessibility in mouse and human tissues
Abstract Cellular function in tissue is dependent on the local environment, requiring new methods for spatial mapping of biomolecules and cells in the tissue context1. The emergence of spatial transcriptomics has enabled genome-scale gene expression mapping2,3,4,5, but the ability to capture spatial epigenetic information of tissue at the cellular level and genome scale is lacking. Here we ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you